{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:53:25Z","timestamp":1769946805672,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier","isbn-type":[{"value":"9780443158711","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM 007750"],"award-info":[{"award-number":["T32GM 007750"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.mie.2023.08.002","type":"book-chapter","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T06:09:56Z","timestamp":1694239796000},"page":"341-368","source":"Crossref","is-referenced-by-count":5,"title":["High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation"],"prefix":"10.1016","member":"78","reference":[{"issue":"8","key":"10.1016\/bs.mie.2023.08.002_bib1","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/acs.molpharmaceut.6b00436","article-title":"Mechanism-based inhibition of CYP3A4 by podophyllotoxin: Aging of an intermediate is important for in vitro\/in vivo correlations","volume":"13","author":"Barnaba","year":"2016","journal-title":"Molecular Pharmaceutics"},{"issue":"4","key":"10.1016\/bs.mie.2023.08.002_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0022-5347(24)07554-2","article-title":"The formation of complexes absorbing at 455 nm from cytochrome P-450 and metabolites of compounds related to SKF 525-A","volume":"2","author":"Buening","year":"1974","journal-title":"Drug Metabolism and Disposition"},{"issue":"2","key":"10.1016\/bs.mie.2023.08.002_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.abb.2005.02.020","article-title":"Cyclopropylamine inactivation of cytochromes P450: Role of metabolic intermediate complexes","volume":"436","author":"Cerny","year":"2005","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib4","first-page":"332","article-title":"Microplate assay measurement of cytochrome p450-carbon monoxide complexes","volume":"36","author":"Choi","year":"2003","journal-title":"Journal of Biochemistry and Molecular Biology"},{"issue":"6","key":"10.1016\/bs.mie.2023.08.002_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/dmd.121.000356","volume":"49","author":"Eng","year":"2020","journal-title":"Drug Metabolism and Disposition"},{"issue":"7","key":"10.1016\/bs.mie.2023.08.002_bib6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1124\/dmd.111.038505","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction","volume":"39","author":"Foti","year":"2011","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib7","first-page":"227","article-title":"Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes","volume":"2","author":"Franklin","year":"1977","journal-title":"Pharmacology & Therapeutics"},{"issue":"22","key":"10.1016\/bs.mie.2023.08.002_bib8","doi-asserted-by":"crossref","first-page":"18481","DOI":"10.1021\/acsomega.2c00960","article-title":"Structural insights on the conversion of cytochrome P450 to P420","volume":"7","author":"Gable","year":"2022","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/bs.mie.2023.08.002_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/biot.201200185","article-title":"Screening for cytochrome P450 expression in Pichia pastoris whole cells by P450-carbon monoxide complex determination","volume":"8","author":"Gudiminchi","year":"2013","journal-title":"Biotechnology Journal"},{"issue":"9","key":"10.1016\/bs.mie.2023.08.002_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nprot.2009.121","article-title":"Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase","volume":"4","author":"Guengerich","year":"2009","journal-title":"Nature Protocols"},{"issue":"24","key":"10.1016\/bs.mie.2023.08.002_bib12","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1074\/jbc.R113.462275","article-title":"Unusual cytochrome p450 enzymes and reactions","volume":"288","author":"Guengerich","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1021\/tx950177k","article-title":"Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital","volume":"9","author":"He","year":"1996","journal-title":"Chemical Research in Toxicology"},{"issue":"2","key":"10.1016\/bs.mie.2023.08.002_bib14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)38021-8","article-title":"Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)","volume":"288","author":"He","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-3565(25)32134-8","article-title":"The characterization of an inhibitory complex formed with cytochrome P-450 and a metabolite of 1,1-disubstituted hydrazines","volume":"214","author":"Hines","year":"1980","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chemical Research in Toxicology"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0026-895X(25)14349-6","volume":"23","author":"Jeffery","year":"1983","journal-title":"Molecular Pharmacology"},{"issue":"12","key":"10.1016\/bs.mie.2023.08.002_bib18","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1021\/acs.jmedchem.9b00917","article-title":"Designing around structural alerts in drug discovery","volume":"63","author":"Kalgutkar","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1389200054021799","article-title":"A comprehensive listing of bioactivation pathways of organic functional groups","volume":"6","author":"Kalgutkar","year":"2005","journal-title":"Current Drug Metabolism"},{"issue":"5","key":"10.1016\/bs.mie.2023.08.002_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Current Drug Metabolism"},{"issue":"5","key":"10.1016\/bs.mie.2023.08.002_bib21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/00032719.2012.738343","article-title":"Microplate assay measurement of small amount of P450","volume":"46","author":"Kaneko","year":"2013","journal-title":"Analytical Letters"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1389200013338478","article-title":"Mechanism-based inactivators as probes of cytochrome P450 structure and function","volume":"2","author":"Kent","year":"2001","journal-title":"Current Drug Metabolism"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.106.117861","article-title":"The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: Metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein","volume":"321","author":"Lin","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.301.1.160","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: Evidence for heme destruction and covalent binding to protein","volume":"301","author":"Lin","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1016\/bs.mie.2023.08.002_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/dmd.118.080903","article-title":"Formation of both heme and apoprotein adducts contributes to the mechanism-based inactivation of human CYP2J2 by 17\u03b1-ethynylestradiol","volume":"46","author":"Lin","year":"2018","journal-title":"Drug Metabolism and Disposition"},{"issue":"2","key":"10.1016\/bs.mie.2023.08.002_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/dmd.110.034074","article-title":"Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1124\/dmd.108.024075","article-title":"Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator?","volume":"37","author":"Linder","year":"2009","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0163-7258(87)90026-X","article-title":"Formation of reactive intermediates and metabolites: Effects of macrolide antibiotics on cytochrome P-450","volume":"33","author":"Mansuy","year":"1987","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/bs.mie.2023.08.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00498250903337392","article-title":"Effects of organic solvents on the time-dependent inhibition of CYP3A4 by diazepam","volume":"40","author":"Nishiya","year":"2010","journal-title":"Xenobiotica; The Fate of Foreign Compounds in Biological Systems"},{"key":"10.1016\/bs.mie.2023.08.002_bib30","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-bindingT pigment of liver microsomes. I. Evidence for its hemoprotein nature","volume":"239","author":"Omura","year":"1964","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/bs.mie.2023.08.002_bib31","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: Structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.mie.2023.08.002_bib32","series-title":"Cytochrome P450 structure, mechanism, and biochemistry","year":"2005"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib33","first-page":"38","article-title":"1-Aminobenzotriazole: A mechanism-based cytochrome P450 inhibitor and probe of cytochrome P450 biology","volume":"8","author":"Ortiz de Montellano","year":"2018","journal-title":"Medicinal Chemistry (Los Angeles)"},{"key":"10.1016\/bs.mie.2023.08.002_bib34","first-page":"137","article-title":"High-throughput carbon monoxide binding assay for cytochromes p450","volume":"230","author":"Otey","year":"2003","journal-title":"Methods in Molecular Biology"},{"issue":"11","key":"10.1016\/bs.mie.2023.08.002_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/00498258209038944","article-title":"Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents","volume":"12","author":"Pershing","year":"1982","journal-title":"Xenobiotica; the Fate of Foreign Compounds in Biological Systems"},{"issue":"5","key":"10.1016\/bs.mie.2023.08.002_bib36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2125.2006.02627.x","article-title":"An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid","volume":"61","author":"Polasek","year":"2006","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/bs.mie.2023.08.002_bib37","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/dmd.105.006825","article-title":"An evaluation of methods for the reconstitution of cytochromes P450 and NADPH P450 reductase into lipid vesicles","volume":"34","author":"Reed","year":"2006","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"43","key":"10.1016\/bs.mie.2023.08.002_bib38","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proceedings of the National Academy of Science United States of America"},{"issue":"6","key":"10.1016\/bs.mie.2023.08.002_bib39","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/dmd.110.037531","article-title":"Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib","volume":"39","author":"Takakusa","year":"2011","journal-title":"Drug Metabolism and Disposition"},{"issue":"9","key":"10.1016\/bs.mie.2023.08.002_bib40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1124\/dmd.112.045302","article-title":"Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metabolism and Disposition"},{"issue":"4","key":"10.1016\/bs.mie.2023.08.002_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jpha.2014.01.001","article-title":"An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes","volume":"4","author":"Wang","year":"2014","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"10.1016\/bs.mie.2023.08.002_bib42","first-page":"61","article-title":"Cytochrome P450 reconstitution systems","volume":"320","author":"Yamazaki","year":"2006","journal-title":"Methods in Molecular Biology"},{"issue":"3","key":"10.1016\/bs.mie.2023.08.002_bib43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.115.067876","article-title":"Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metabolism and Disposition"},{"issue":"6","key":"10.1016\/bs.mie.2023.08.002_bib44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/dmd.110.037911","article-title":"CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs","volume":"39","author":"Zimmerlin","year":"2011","journal-title":"Drug Metabolism and Disposition"}],"container-title":["Methods in Enzymology","Modern Methods of Drug Design and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0076687923002537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0076687923002537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:09:53Z","timestamp":1761844193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0076687923002537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443158711"],"references-count":44,"URL":"https:\/\/doi.org\/10.1016\/bs.mie.2023.08.002","relation":{},"ISSN":["0076-6879"],"issn-type":[{"value":"0076-6879","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}